Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

PHASE3RecruitingINTERVENTIONAL

Enrollment

208

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2028

Conditions

Glomerulonephritis, IGA

Interventions

DRUG

Prednisolone

RAS blockade as much as tolerated or allowed

DRUG

Prednisolone plus Cyclophosphamide

RAS blockade as much as tolerated or allowed

Trial Locations (1)

RECRUITING

AFMMU, Xi'an

All Listed Sponsors

lead

Air Force Military Medical University, China

OTHER